Fiche publication
Date publication
janvier 2021
Journal
Crohn's & colitis 360
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Solitano V, D'Amico F, Da Rio L, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
With the expiration of biologics' patents, biosimilars entered the market as a promising opportunity to reduce health-care costs in the field of inflammatory bowel diseases. Although biosimilars were initially poorly accepted, the growing evidence about their efficacy and safety has changed this situation, resulting in their widespread use. However, there is still an unmet need of improving patients' education about biosimilars to minimize nocebo responses and to accept nonmedical switching. Looking to the future, the use of recently authorized adalimumab biosimilars and the first attempts of adopting different strategies of switching (eg, cross-, multiple-) will fill some residual knowledge gaps.
Mots clés
Europe, biosimilars, inflammatory bowel diseases, switching
Référence
Crohns Colitis 360. 2021 01;3(1):otab012
